AIM ImmunoTech Complete Safety Evaluation Of Patents Enrolled For Phase 1b/2 Study Of Ampligen And Imfinzi As Combination Therapy For Late-Stage Pancreatic Cancer
AIM ImmunoTech完成了對Ampligen和Imfinzi作爲晚期胰腺癌聯合療法的1b/2期研究註冊專利的安全性評估
AIM ImmunoTech Complete Safety Evaluation Of Patents Enrolled For Phase 1b/2 Study Of Ampligen And Imfinzi As Combination Therapy For Late-Stage Pancreatic Cancer
AIM ImmunoTech完成了對Ampligen和Imfinzi作爲晚期胰腺癌聯合療法的1b/2期研究註冊專利的安全性評估
使用瀏覽器的分享功能,分享給你的好友吧